Safety, Efficacy and Determinants of Response of Allogeneic CD19-Specific CAR-NK Cells in CD19+ B Cell Tumors: A Phase I/II Trial

Investigators conducted a Phase I/II trial of cord blood-derived natural killer cells expressing anti-CD19 chimeric antigen receptor and interleukin-15 in 37 patients with CD19+ B cell malignancies.